Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Cincinnati
With
Astellas Pharma Inc
To determine the safety and efficacy of early corticosteroid discontinuation in liver transplant recipients more than 90 days post transplant, utilizing a combination of two drugs (tacrolimus and mycophenolate mofetil) for maintenance immunosuppression therapy.
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Greater than 90 days post transplant.
Free from rejection within the last 30 days.
Patient with primary diagnosis of AIH will be evaluated on an individual basis.
Negative pregnancy test.
Practicing an acceptable method of birth control.
Capable of providing written informed consent.
You may not be if
Rejection within the last 30 days.
Patients with AIH unable to discontinue corticosteroids.
Patients currently receiving systemic corticosteroids for other medical diseases in which the physician feels discontinuation is contraindicated.
Known sensitivity or contraindication to tacrolimus or MMF.
Kidney, pancreas, islet, heart, lung, or small bowel transplant recipient.
Pregnant or lactating.
Clareo Health | Single Center Pilot Study of Corticosteroid Discontinuation in Liver Transplant Recipients
